Inhibitory effect of the novel anti-estrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[a]anthracene-induced mammary carcinoma in rats

International Journal of Cancer

Volumn 73, Issue 4, 1997, Pages 580-586

  Luo, Shouqi ^a   Stojanovic, Milos ^a   Labrie, Claude ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACENE DERIVATIVE; ANTIESTROGEN; MEDROXYPROGESTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; DOSE RESPONSE; DRUG POTENCY; LUTEINIZING HORMONE BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RAT; RECEPTOR BINDING; TUMOR GROWTH;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADRENAL GLANDS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOPYRANS; CARCINOGENS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGEN ANTAGONISTS; ESTRONE; FEMALE; LUTEINIZING HORMONE; MAMMARY NEOPLASMS, EXPERIMENTAL; MEDROXYPROGESTERONE 17-ACETATE; ORGAN SIZE; PROPIONATES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; UTERUS; VAGINA;

EID: 0031437691     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971114)73:4<580::AID-IJC20>3.0.CO;2-C     Document Type: Article

References (48)

1. ASSELIN, J., KELLY, P.A., CARON, M.G. and LABRIE, F., Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin. Endocrinology, 101, 666-671 (1977).
2. ASSELIN, J. and LABRIE, F., Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat. J. Steroid Biochem., 9, 1079-1082 (1978).
3. BOCCARDO, F., CERRUTI, G., DE MENECH, R., VALENTI, G. and ZANARDI, S., Priming action on progesterone receptor synthesis by estradiol and tamoxifen in the 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinoma. Oncology, 44, 248-252 (1987).
4. BRADFORD, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254 (1976).
5. DAUVOIS, S., DANIELIAN, P.S., WHITE, R. and PARKER, M.G., Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. nat. Acad. Sci. (Wash.), 89, 4037-4041 (1992).
6. DAUVOIS, S., GENG, C.S., LÉVESQUE, C., MÉRAND, Y. and LABRIE, F., Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res., 51, 3131-3135 (1991).
7. DAUVOIS, S., LI, S., MARTEL, C. and LABRIE, F., Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat. Breast Cancer Res. Treat., 14, 299-306 (1989a).
8. DAUVOIS, S., SPINOLA, P.G. and LABRIE, F., Additive inhibitory effects of bromocriptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat. Europ. J. Cancer clin. Oncol., 25, 891-897 (1989b).
9. DE LAUNOIT, Y. DAUVOIS, S., DUFOUR, M., SIMARD, J. and LABRIE, F., Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-l l-(16′α-chloro-3′,17β-dihydroxy-estra-1′,3′, 5′-(10′) triene-7′ α-yl)undecanamide in human breast cancer ZR-75-1 cells. Cancer Res., 51, 2797-2802 (1991).
10. DUKES, M., MILLER, D., WAKELING, A.E. and WATERTON, J.C., Antiuterotrophic effects of a pure antioestrogen. ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J. Endocrinol., 135, 239-247 (1992).
11. ECKERT, R.L., MULLICK, A., RORKE, E.A. and KATZENELLENBOGEN, B.S., Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology, 114, 629-637 (1984).
12. FERLAND, L., DROUIN, J. and LABRIE, F., Role of sex steroids on LH and FSH secretion in the rat. In: F. Labrie, J. Meites and G. Pelletier (eds.), Hypothalamus and endocrine functions, pp. 191-209, Plenum Press, New York (1976).
13. FURR, B.J. and JORDAN, V.C., The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25, 127-205 (1984).
14. GAUTHIER, S. and 15 OTHERS, (S)-(+)-[4-[7-(2,2-Dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J. med. Chem., 40, 2117-2122 (1997).
15. HALLER, D.G. and GLICK, J.H., Progestational agents in advanced breast cancer: an overview. Semin. Oncol., 13 (Suppl.), 2-8 (1986).
16. HORWITZ, K.B. and MCGUIRE, W.L., Nuclear mechanism of estrogen action. Effect of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J. biol. Chem., 253, 8185-8191 (1978).
17. INGLE, J.N., TWITO, D.I., SCHAID, D.J., CULLINAN, S.A., KROOK, J.E., MAILLIARD, J.A., TSCHETTER, L.K., LONG, H.J., GERSTNER, J.G., WINDSCHITL, H.E., LEVITT, R. and PFEIFLE, D.M., Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. Cancer, 67, 886-891 (1991).
18. JAMIL, A., CROXTALL, J.D. and WHITE, J.O., The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa). J. mol. Endocrinol., 6, 215-221 (1991).
19. JORDAN, V.C., ALLEN. K.E. and DIX, C.J., Pharmacology of tamoxifen in laboratory animals. Cancer Treat. Rep., 64, 745-759 (1980).
20. KIVINEN, S. and MAENPAA, J., Effect of toremifene on clinical chemistry, hematology and hormone levels at different doses in healthy postmenopausal volunteers: phase I study. J. Steroid Biochem., 36, 217-220 (1990).
21. KRAMER, C.Y., Extension of multiple range tests to group means with unique numbers of replications. Biometrics, 12, 307-310 (1956).
22. LABRIE, F., Intracrinology. Mol. cell. Endocrinol., 78, C113-C118 (1991).
23. LABRIE, C., BÉLANGER, A. and LABRIE, F., Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 123, 1412-1417 (1988).
24. LABRIE, C., CUSAN, L., PLANTE, M., LAPOINTE, S. and LABRIE, F., Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. J. Steroid Biochem., 28, 379-384 (1987).
25. LABRIE, F., LI, S., BÉLANGER, A., CÔTÉ, J., MÉRAND, Y. and LEPAGE, M., Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethylbenz(a)anthracene in the rat. Breast Cancer Res. Treat., 26, 253-265 (1993).
26. LI, S., LEPAGE, M., MÉRAND, Y., BÉLANGER, A. and LABRIE, F., Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate. Breast Cancer Res. Treat., 24, 127-137 (1992).
27. LI, S., LÉVESQUE, C., GENG, C.S., YAN, X. and LABRIE, F., Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res. Treat., 34, 147-159 (1995).
28. LI, S., MARTEL, C., DAUVOIS, S., BÉLANGER, A. and LABRIE, F., Effect of estrone on the growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat: a model of post-menopausal breast cancer. Endocrinology, 134, 1352-1357 (1994).
29. MAY, F.E., JOHNSON, M.D., WISEMAN, L.R., WAKELING, A.E., KASTNER, P. and WESTLEY, B.R., Regulation of progesterone receptor mRNA by oestradiol and antioestrogens in breast cancer cell lines. J. Steroid. Biochem., 33, 1035-1041 (1989).
30. MCGUIRE, W.L., CARBONE, P.P., SEARD, M.E. and ESCHE, G.C., Estrogen receptors in human breast cancer: an overview. In: W.L. McGuire, P.P. Carbone and E.P. Vollmer (eds.), Estrogen receptors in human breast cancer, pp. 1-7, Raven Press, New York (1975).
31. MILLER, W.R., Fundamental research leading to improved endocrine therapy for breast cancer. J. Steroid Biochem., 27, 477-485 (1987).
32. PASQUALINI, J.R., GIAMBIAGI, N., GELLY, C. and CHETRITE, G., Antiestrogen action in mammary cancer and in fetal cells. J. Steroid. Biochem. mol. Biol., 37, 343-348 (1990).
33. POULIN, R., BAKER, D. and LABRIE, F., Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res. Treat., 12, 213-225 (1988).
34. POULIN, R., BAKER, D., POIRIER, D. and LABRIE, F., Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res. Treat., 13, 161-172 (1989a).
35. POULIN, R., BAKER, D., POIRIER. D. and LABRIE, F., Multiple actions of synthetic "progestins"on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen and glucocorticoid agonistic and antagonistic activities of compounds. Breast Cancer Res. Treat., 17, 197-210 (1991).
36. 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res., 46, 4933-4937 (1986).
37. POULIN, R., MÉRAND, Y., POIRIER, D., LÉ VESQUE, C., DUFOUR, J.M. and LABRIE, F., Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxi-fen and ICI164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells. Breast Cancer Res. Treat., 14, 65-76 (1989b).
38. SHTERI, P.K. and MACDONALD, P.C., The role of extraglandular estrogen in human endocrinology. In: S.R. Freiger, E.B. Astwood and R.O. Greep (eds.), Handbook of physiology, Section 7, pp. 615-619, American Physiological Society, Washington, DC (1973).
39. SIMARD, J., DAUVOIS, S., HAAGENSEN, D.E., LÉVESQUE, C., MÉRAND, Y. and LABRIE, F., Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. Endocrinology, 126, 3223-3231 (1990).
40. SIMARD, J., DE LAUNOIT, Y., HAAGENSEN, D.E. and LABRIE, F., Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells. Endocrinology, 130, 1115-1121 (1992).
41. SIMARD, J., HATTON, A.C., LABRIE, C., DAUVOIS, S., ZHAO, H.F., HAAGENSEN, D.E. and LABRIE, F., Inhibitory effects of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. Mol. Endocrinol., 3, 694-702 (1989).
42. SIMARD, J., LABRIE, C., BÉLANGER, A., GAUTHIER, S., SINGH, S.M., MÉRAND, Y. and LABRIE, F., Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer, 73, 104-112 (1997).
43. SWEDISH BREAST CANCER COOPERATIVE GROUP, Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J. nat. Cancer Inst., 88, 1543-1549 (1996).
44. TORMEY, D.C., LIPPMAN, M.E., EDWARDS, B.K. and CASSIDY, J.G., Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann. int. Med., 98, 139-144 (1983).
45. WAKELING, A.E. and BOWLER, J., Biology and mode of action of pure antiestrogens. J. Steroid Biochem., 30, 141-147 (1988).
46. WAKELING, A.E., DUKES. M. and BOWLER, J., A potent specific pure antiestrogen with clinical potential. Cancer Res., 51, 3867-3873 (1991).
47. WELLS JR, S.A. and SANTEN, R.J., Ablative procedures in patients with metastatic breast carcinoma. Cancer, 53, 762-765 (1984).
48. WELSCH, C.W., Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res., 45, 3415-3443 (1985).